Kabra Drugs Ltd (524322)

Aanjaay Industries Limited (formerly known as Kabra Drugs Limited) submitted a statement of non-applicability of Regulation 32 of SEBI LODR Regulations for the quarter ended September 30, 2026. The company confirmed that no shares were issued via public issue, rights issue, or preferential issue during the quarter. Consequently, reporting on deviation or variation in proceeds utilization is not applicable. This is a standard quarterly compliance filing with no operational or financial impact.

• Regulation 32 compliance declared non-applicable for the quarter ended September 30, 2026
• No funds raised via public, rights, or preferential issues during the quarter
• Filing signed by Managing Director Nanjappan Aravind on November 06, 2026

Aanjaay Industries (formerly Kabra Drugs Ltd) reported Q2 FY27 revenue from operations of ₹31.95 Cr, up 61.7% YoY from ₹19.76 Cr in Q2 FY26, though down 30.9% QoQ from ₹46.22 Cr. Net profit for the quarter stood at ₹1.92 Cr, up 4.6% YoY compared to ₹1.84 Cr in Q2 FY26, but lower by 9.5% QoQ compared to ₹2.12 Cr. Exceptional items included a bad debt write-off of ₹9.61 Lakhs. Operating cash flow for H1 FY27 remained negative at -₹8.59 Cr compared to -₹9.46 Cr in FY26.

• Revenue from operations grew 61.7% YoY to ₹3,195.36 Lakhs (₹31.95 Cr) in Q2 FY27 from ₹1,976.40 Lakhs in Q2 FY26
• Net profit after tax stood at ₹192.18 Lakhs (₹1.92 Cr) vs ₹183.68 Lakhs in Q2 FY26 and ₹212.30 Lakhs in Q1 FY27
• Basic EPS for the quarter was ₹0.81 compared to ₹0.77 in Q2 FY25/26 and ₹0.90 in Q1 FY27
• Recognized exceptional bad debts written off of ₹9.61 Lakhs in Q2 FY27
• Trade receivables significantly decreased to ₹1,228.26 Lakhs as of Sep 30, 2026 from ₹7,077.60 Lakhs as of Mar 31, 2026

Kabra Drugs Ltd (Aanjaay Industries Limited) has informed BSE that its Board of Directors will meet on November 6, 2026. The board will consider and approve the unaudited financial results for the quarter ended September 30, 2026. This is a routine regulatory intimation pursuant to Regulation 29 of SEBI LODR Regulations.

• Board meeting scheduled for November 6, 2026
• Meeting agenda includes approval of unaudited results for quarter ended September 30, 2026
• Intimation filed on October 30, 2026 under Regulation 29 of SEBI LODR Regulations

Kabra Drugs Ltd (Aanjaay Industries Limited) has completed the relocation of its registered office from Indore, Madhya Pradesh to West Mambalam, Chennai, Tamil Nadu. The inter-state shift was approved by the Regional Director on August 13, 2026, and registered with ROC Chennai on August 28, 2026. This administrative update follows the statutory approvals under Section 13(5) of the Companies Act, 2013, with paid-up capital standing at Rs 23.71 Cr.

• Registered office shifted from Indore, MP (ROC Gwalior) to Chennai, Tamil Nadu (ROC Chennai)
• Shift effective from August 28, 2026 following RD order dated August 13, 2026
• Paid-up capital reported at Rs 23,70,78,500 against an authorised capital of Rs 40,00,00,000

Kabra Drugs Ltd (now Aanjaay Industries Limited) has scheduled a Board of Directors meeting on September 2, 2026. The board will approve the Directors' Report for the financial year ended March 31, 2026, and finalize the date and cut-off details for the upcoming Annual General Meeting (AGM). Additional agenda items include the re-appointment of director Mr. Kuniamuthur Nanjappan Anand, the proposed appointment of Ms. Moonam Kapoor as director, and appointment of internal and secretarial auditors.

• Board meeting scheduled for September 2, 2026 at the Corporate Office in Chennai
• Meeting to approve the Directors' Report and Corporate Governance Report for FY ended March 31, 2026
• To propose the appointment of Ms. Moonam Kapoor (DIN: 09278005) as Director
• To recommend Secretarial Auditor appointment for FY 2026-2027 to 2030-2031

Kabra Drugs Limited (formerly known as Aanjaay Industries Limited) announced the reconstitution of its Board of Directors and key committees with effect from August 12, 2026. The 5-member board consists of 2 Executive Directors and 3 Non-Executive Independent Directors, led by Managing Director Nanjappan Aravind. The Audit, Nomination & Remuneration, and Stakeholders Relationship Committees have also been restructured with independent director majorities.

• Reconstitution of Board and committees effective August 12, 2026
• Board comprises 5 total directors: 2 Executive and 3 Independent Non-Executive Directors
• Audit Committee reconstituted with 3 members, chaired by Independent Director Nikita Sinha
• Nomination & Remuneration Committee formed with 3 members, chaired by Independent Director Ritu Tiwari

Ms. Anand Anitha has resigned from her position as Director of Kabra Drugs Ltd (now Aanjaay Industries Limited) effective August 12, 2026. The resignation is attributed to personal reasons, with the director confirming there are no other material reasons for her departure. This management change occurs as the company, with a market capitalization of ₹56 Cr, manages a significant scale-up from zero revenue in FY25 to ₹92.74 Cr in FY26. The board has taken note of the resignation following recommendations from the Nomination and Remuneration Committee.

• Resignation of Ms. Anand Anitha effective from August 12, 2026
• Director confirmed no other material reasons for resignation beyond personal grounds
• Company reported FY26 revenue of ₹92.74 Cr compared to zero in FY25
• Current Market Capitalization stands at ₹56 Cr

Aanjaay Industries Limited (formerly Kabra Drugs Limited) has submitted a formal undertaking to the BSE regarding Regulation 32 of SEBI (LODR). The company confirmed that it did not raise any funds through public, rights, or preferential issues for the quarter ended June 30, 2026. Consequently, there are no deviations or variations in the utilization of proceeds to report. This is a standard procedural filing required by listed entities to ensure transparency in fund usage.

• Reporting period ended June 30, 2026.
• Zero shares issued via public, rights, or preferential routes during the quarter.
• Filing submitted on August 12, 2026, as per SEBI (LODR) requirements.

Kabra Drugs Ltd (now Aanjaay Industries) has scheduled a board meeting for August 12, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The board will also consider the resignation of Director Ms. Anand Anitha. This meeting follows a high-growth FY26 where the company scaled revenue to Rs 92.74 Cr from zero in FY25. Investors should focus on whether the company can maintain its TTM operating margin of 5.7% and the revenue momentum seen in the March 2026 quarter (Rs 35.41 Cr).

• Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results.
• Resignation of Director Ms. Anand Anitha (DIN: 02040505) to be formally considered.
• Trading window for insiders is closed until 48 hours after the results announcement.
• Company reported a significant turnaround in FY26 with Rs 4.96 Cr PAT vs a loss of Rs 1.09 Cr in FY25.